董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Albert G. White III | 男 | Chief Executive Officer,Director and President | 56 | 1605.11万美元 | 194.49 | 2026-04-07 |
| Colleen E. Jay | 女 | Chairman of the Board and Director | 63 | 35.50万美元 | 3.66 | 2026-04-07 |
| Teresa S. Madden | 女 | Independent Director | 69 | 36.00万美元 | 1.24 | 2026-04-07 |
| Maria Rivas | 女 | Independent Director | 62 | 33.50万美元 | 1.11 | 2026-04-07 |
| Barbara Carbone | 女 | Independent Director | 67 | 28.00万美元 | 未持股 | 2026-04-07 |
| Cynthia L. Lucchese | 女 | Independent Director | 65 | 34.87万美元 | 0.94 | 2026-04-07 |
| Robert S. Weiss | 男 | Independent Director | 79 | 48.70万美元 | 54.68 | 2026-04-07 |
| Lawrence E. Kurzius | 男 | Independent Director | 67 | 33.50万美元 | 0.78 | 2026-04-07 |
| Walter M Rosebrough, Jr. | 男 | Independent Director | 72 | 未披露 | 1.00 | 2026-04-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Albert G. White III | 男 | Chief Executive Officer,Director and President | 56 | 1605.11万美元 | 194.49 | 2026-04-07 |
| Brian G. Andrews | 男 | Executive Vice President, Chief Financial Officer & Treasurer | 47 | 433.77万美元 | 35.00 | 2026-04-07 |
| Holly R. Sheffield | 女 | President, CooperSurgical, Inc. | 55 | 365.67万美元 | 35.78 | 2026-04-07 |
| Gerard H. Warner III | 男 | President, CooperVision, Inc. | 61 | 364.48万美元 | 9.11 | 2026-04-07 |
| Daniel G. McBride | 男 | Executive Vice President, Chief Operating Officer, General Counsel & Secretary | 61 | 482.30万美元 | 68.58 | 2026-04-07 |
董事简历
中英对照 | 中文 | 英文- Albert G. White III
-
Albert G. White III，他曾担任The Cooper Companies， Inc.的总裁兼首席执行官和成员。自2018年5月起担任董事会成员。此前，他从2016年11月起担任首席财务官，直到被任命为首席执行官，他还分别从2015年12月和2011年7月担任执行副总裁和首席战略官。从2015年8月到2018年5月，White先生还负责The Cooper Companies， Inc.的女性医疗保健业务，并担任Cooper Medical Inc. （CooperSurgical的母公司）的首席执行官。此前，他从2007年11月到2013年3月担任投资者关系副总裁，从2006年4月到2012年12月担任副总裁兼财务主管。在加入本公司之前，White先生曾担任KeyBank Capital Markets董事三年，并在KeyBank National Association担任多个领导职位。他持有Virginia Tech的金融学士学位和工商管理硕士学位。
Albert G. White III has served as President & Chief Executive Officer and as a member of Board of Directors since May 2018. Under his leadership, CooperCompanies has developed into a unified, synergistic operating company and global medical device leader – driving strong revenue and profit growth through organizational evolution while elevating CooperVision to the world's #1 contact lens company by arers and CooperSurgical to the global leader in fertility devices and a U.S. leader in highrisk labor and delivery safety. Prior to his appointment as CEO, Mr. White served in vario leadership roles across CooperCompanies, developing an intimate understanding of the biness and its markets. He served as Chief Financial Officer from November 2016 to May 2018 and as EVP and Chief Strategy Officer beginning in 2015 and 2011, respectively. From Augt 2015 to May 2018, he also led the Company's women's healthcare biness and served as CEO of Cooper Medical Inc., the parent company of CooperSurgical. Earlier in his tenure at CooperCompanies, he held the roles of VP, Investor Relations (2007–2013) and VP and Treasurer (2006–2012). Before joining CooperCompanies, Mr. White spent three years as a Director at KeyBanc Capital Markets and held numero positions of increasing responsibility within KeyBank National Association over the prior eight years. Mr. White also serves as a memer of the Board of Directors of Evol, Inc. (NASDAQ: EOLS), a performance beauty company building an aesthetic portfolio of consumer brands. He is Chair of the Compensation Committee and a member of the Audit Committee. Mr. White holds a B.S. in Finance and an MBA, both from Virginia Tech. - Albert G. White III，他曾担任The Cooper Companies， Inc.的总裁兼首席执行官和成员。自2018年5月起担任董事会成员。此前，他从2016年11月起担任首席财务官，直到被任命为首席执行官，他还分别从2015年12月和2011年7月担任执行副总裁和首席战略官。从2015年8月到2018年5月，White先生还负责The Cooper Companies， Inc.的女性医疗保健业务，并担任Cooper Medical Inc. （CooperSurgical的母公司）的首席执行官。此前，他从2007年11月到2013年3月担任投资者关系副总裁，从2006年4月到2012年12月担任副总裁兼财务主管。在加入本公司之前，White先生曾担任KeyBank Capital Markets董事三年，并在KeyBank National Association担任多个领导职位。他持有Virginia Tech的金融学士学位和工商管理硕士学位。
- Albert G. White III has served as President & Chief Executive Officer and as a member of Board of Directors since May 2018. Under his leadership, CooperCompanies has developed into a unified, synergistic operating company and global medical device leader – driving strong revenue and profit growth through organizational evolution while elevating CooperVision to the world's #1 contact lens company by arers and CooperSurgical to the global leader in fertility devices and a U.S. leader in highrisk labor and delivery safety. Prior to his appointment as CEO, Mr. White served in vario leadership roles across CooperCompanies, developing an intimate understanding of the biness and its markets. He served as Chief Financial Officer from November 2016 to May 2018 and as EVP and Chief Strategy Officer beginning in 2015 and 2011, respectively. From Augt 2015 to May 2018, he also led the Company's women's healthcare biness and served as CEO of Cooper Medical Inc., the parent company of CooperSurgical. Earlier in his tenure at CooperCompanies, he held the roles of VP, Investor Relations (2007–2013) and VP and Treasurer (2006–2012). Before joining CooperCompanies, Mr. White spent three years as a Director at KeyBanc Capital Markets and held numero positions of increasing responsibility within KeyBank National Association over the prior eight years. Mr. White also serves as a memer of the Board of Directors of Evol, Inc. (NASDAQ: EOLS), a performance beauty company building an aesthetic portfolio of consumer brands. He is Chair of the Compensation Committee and a member of the Audit Committee. Mr. White holds a B.S. in Finance and an MBA, both from Virginia Tech.
- Colleen E. Jay
-
Colleen E. Jay，目前担任Catalyst, Inc.（一个非盈利组织，致力于改善女性的职场包容的公司）的租借高管。她从Procter & Gamble（NYSE：PG，一个美国跨国消费品公司）借调。她于2016年10月担任Catalyst公司的贷款执行官，也曾担任Procter & Gamble的美容专业业务总裁（始于2015年），也曾负责威娜专业沙龙、化妆品、零售染发和香水业务。担任美容专业业务领导之前，她曾领导Procter & Gamble公司的全球零售护发和颜色部门（2012年至2015年），以及全球女性美容部门（从2010年到2012年）。她也曾担任副总裁兼总经理，负责大中华区女性护理、个人清洁、口腔护理和整个中国营销功能（2006年至2009年），在那里她曾负责总价值超过10亿美元的业务。她曾担任Procter & Gamble公司的多种职务（1985年7月以来），并在职业生涯中也曾领导美国、加拿大、中国和瑞士运营单位，包括全球领先企业。
Colleen E. Jay is a distinguished global Fortune 500 leader with nearly 35 years of experience running multinational, multibillion dollar binesses, has deep expertise in innovation, brand building, organizational leadership, strategic alternatives, and transformational growth. As Chairman of the Board, she adds extensive board and committee leadership and a strong understanding of CooperCompanies' biness, backed by a proven executive track record of driving strategy, operational excellence, and stained value creation. Ms. Jay served as a Global Division President for Procter and Gamble (P&G) (NYSE:PG) until her retirement in October 2017, after 32 years with the multi national consumer goods company leading large global ($8 $15 billion) binesses and organizations. Her most recent operational role was President of the Global Beauty Specialty Biness, where beginning in 2015 she led the lla Professional Salon, Cosmetics, Retail Hair Color, and Fragrance binesses and oversaw their successful divestiture. From 2012 to 2015, she led P&G's multi billion dollar Global Retail Hair Care and Color division, including the billion dollar Pantene and Head & Shoulders brands, and from 2010 to 2012 she served as President of the Global Female Beauty division. She also served as VP & General Manager, Greater China from 2006 to 2009. She worked in vario positions with P&G since 1985 and has resided in/led operational units in the United States, Canada, China, and Europe. Ms. Jay serves on the board of Treasury Wine Estates (ASX: T), a publicly traded company making and selling wine for the global market. She also serves on the board of Beyond Meat, Inc. (NASDAQ: BYND) and is Chair of the Human Capital and Compensation Committee and a member of the Risk Committee. - Colleen E. Jay，目前担任Catalyst, Inc.（一个非盈利组织，致力于改善女性的职场包容的公司）的租借高管。她从Procter & Gamble（NYSE：PG，一个美国跨国消费品公司）借调。她于2016年10月担任Catalyst公司的贷款执行官，也曾担任Procter & Gamble的美容专业业务总裁（始于2015年），也曾负责威娜专业沙龙、化妆品、零售染发和香水业务。担任美容专业业务领导之前，她曾领导Procter & Gamble公司的全球零售护发和颜色部门（2012年至2015年），以及全球女性美容部门（从2010年到2012年）。她也曾担任副总裁兼总经理，负责大中华区女性护理、个人清洁、口腔护理和整个中国营销功能（2006年至2009年），在那里她曾负责总价值超过10亿美元的业务。她曾担任Procter & Gamble公司的多种职务（1985年7月以来），并在职业生涯中也曾领导美国、加拿大、中国和瑞士运营单位，包括全球领先企业。
- Colleen E. Jay is a distinguished global Fortune 500 leader with nearly 35 years of experience running multinational, multibillion dollar binesses, has deep expertise in innovation, brand building, organizational leadership, strategic alternatives, and transformational growth. As Chairman of the Board, she adds extensive board and committee leadership and a strong understanding of CooperCompanies' biness, backed by a proven executive track record of driving strategy, operational excellence, and stained value creation. Ms. Jay served as a Global Division President for Procter and Gamble (P&G) (NYSE:PG) until her retirement in October 2017, after 32 years with the multi national consumer goods company leading large global ($8 $15 billion) binesses and organizations. Her most recent operational role was President of the Global Beauty Specialty Biness, where beginning in 2015 she led the lla Professional Salon, Cosmetics, Retail Hair Color, and Fragrance binesses and oversaw their successful divestiture. From 2012 to 2015, she led P&G's multi billion dollar Global Retail Hair Care and Color division, including the billion dollar Pantene and Head & Shoulders brands, and from 2010 to 2012 she served as President of the Global Female Beauty division. She also served as VP & General Manager, Greater China from 2006 to 2009. She worked in vario positions with P&G since 1985 and has resided in/led operational units in the United States, Canada, China, and Europe. Ms. Jay serves on the board of Treasury Wine Estates (ASX: T), a publicly traded company making and selling wine for the global market. She also serves on the board of Beyond Meat, Inc. (NASDAQ: BYND) and is Chair of the Human Capital and Compensation Committee and a member of the Risk Committee.
- Teresa S. Madden
-
Teresa S. Madden从2011年至2016年退休，担任电力和天然气公用事业XCEL Energy，Inc.（NASDAQ：XEL）的执行副总裁兼首席财务官。她于2003年加入XCEL，担任财务、客户和外地业务副总裁，并于2004年被任命为副总裁兼财务总监。她曾于2000年至2003年担任Rogue Wave Software，Inc.的财务总管；2004年1月到2011年9月担任Xcel能源服务有限公司副总裁和总监并担任XCEL Energy前身公司科罗拉多新世纪能源和公共服务公司的财务总管，自2011年9月至今担任Xcel能源服务有限公司高级副总裁和首席财务官。Madden女士拥有科罗拉多州立大学会计学学士学位和里吉斯大学工商管理硕士学位。Madden女士在Enbridge，Inc.（NYSE：ENB）董事会任职，并担任治理委员会成员和审计主席，财务和风险委员会，此前她曾在2017年至2020年担任皮博迪能源公司（NYSE：BTU）董事，曾在健康、安全、安保和环境委员会任职，并担任审计委员会主席。
Teresa S. Madden is an accomplished financial executive and active CPA with more than three decades of public company experience, having led all finance functions as CFO of a Fortune 300 company and through additional financial oversight through her service on public company audit committees. Ms. Madden served as EVP and Chief Financial Officer of Xcel Energy, Inc. (NASDAQ: XEL) from 2011 to until her retirement in 2016 with responsibility for all financial functions, including controllership, treasury, tax, risk management, internal audit, budgeting and forecasting, investor relations, regulatory revenue requirements, and corporate development. At Xcel, Ms. Madden was directly responsible for managing an annual capital investment spend in excess of $3 billion and external financing requirements ranging from $1 $2 billion. From 2004 to 2011, she served as VP, Controller & Principal Accounting Officer, and from 2003 to 2004 as VP of Finance for Ctomer & Field Operations. Prior to these roles, she served as Corporate Controller & Interim Chief Financial Officer at Rogue Wave Software from 2000 to 2003, Corporate Controller & Principal Accounting Officer at New Century Energies from 1997 to 2000 and held progressively senior financial positions at Public Service Company of Colorado from 1979 to 1997. Ms. Madden serves on the board of Enbridge, Inc. (NYSE: ENB) and serves on the governance committee and as chair of the audit, finance and risk committee. She previoly served as a director for Peabody Energy Corporation (NYSE: BTU) from 2017 to 2020 where she served on the health, safety, security & environmental committee and as chair of the audit committee. She holds a B.S. in Accounting from Colorado State University and an MBA from Regis University and maintains an active Colorado CPA license. - Teresa S. Madden从2011年至2016年退休，担任电力和天然气公用事业XCEL Energy，Inc.（NASDAQ：XEL）的执行副总裁兼首席财务官。她于2003年加入XCEL，担任财务、客户和外地业务副总裁，并于2004年被任命为副总裁兼财务总监。她曾于2000年至2003年担任Rogue Wave Software，Inc.的财务总管；2004年1月到2011年9月担任Xcel能源服务有限公司副总裁和总监并担任XCEL Energy前身公司科罗拉多新世纪能源和公共服务公司的财务总管，自2011年9月至今担任Xcel能源服务有限公司高级副总裁和首席财务官。Madden女士拥有科罗拉多州立大学会计学学士学位和里吉斯大学工商管理硕士学位。Madden女士在Enbridge，Inc.（NYSE：ENB）董事会任职，并担任治理委员会成员和审计主席，财务和风险委员会，此前她曾在2017年至2020年担任皮博迪能源公司（NYSE：BTU）董事，曾在健康、安全、安保和环境委员会任职，并担任审计委员会主席。
- Teresa S. Madden is an accomplished financial executive and active CPA with more than three decades of public company experience, having led all finance functions as CFO of a Fortune 300 company and through additional financial oversight through her service on public company audit committees. Ms. Madden served as EVP and Chief Financial Officer of Xcel Energy, Inc. (NASDAQ: XEL) from 2011 to until her retirement in 2016 with responsibility for all financial functions, including controllership, treasury, tax, risk management, internal audit, budgeting and forecasting, investor relations, regulatory revenue requirements, and corporate development. At Xcel, Ms. Madden was directly responsible for managing an annual capital investment spend in excess of $3 billion and external financing requirements ranging from $1 $2 billion. From 2004 to 2011, she served as VP, Controller & Principal Accounting Officer, and from 2003 to 2004 as VP of Finance for Ctomer & Field Operations. Prior to these roles, she served as Corporate Controller & Interim Chief Financial Officer at Rogue Wave Software from 2000 to 2003, Corporate Controller & Principal Accounting Officer at New Century Energies from 1997 to 2000 and held progressively senior financial positions at Public Service Company of Colorado from 1979 to 1997. Ms. Madden serves on the board of Enbridge, Inc. (NYSE: ENB) and serves on the governance committee and as chair of the audit, finance and risk committee. She previoly served as a director for Peabody Energy Corporation (NYSE: BTU) from 2017 to 2020 where she served on the health, safety, security & environmental committee and as chair of the audit committee. She holds a B.S. in Accounting from Colorado State University and an MBA from Regis University and maintains an active Colorado CPA license.
- Maria Rivas
-
Maria Rivas目前担任the healthcare business of Merck KGaA, Darmstadt的首席医疗官和高级副总裁。the healthcare business of Merck KGaA, Darmstadt在美国和加拿大担任EMD Serono，领导全球90多个国家的药物警戒、医疗事务和证据与价值开发（HEOR）团队。Rivas博士在推动高度监管行业的增长和商业化战略、全球运营、数字转型以及危机和风险管理方面有经验。在此之前，Rivas博士曾担任默克公司（MSD）全球医疗事务高级副总裁、Abbvie全球医疗事务副总裁、拜耳医疗集团肿瘤学、普通医学和诊断成像医学事务副总裁，在礼来担任各种职务，包括美国妇女健康医疗事务负责人。在加入礼来公司之前，Rivas博士在波多黎各私人执业，担任内分泌学家。Rivas博士在马萨诸塞州沃尔瑟姆的布兰代斯大学获得了生物化学学士学位，并在纽约哥伦比亚大学瓦杰洛斯内科医生和外科医生学院获得了医学博士学位。她在纽约州纽约长老会医院完成了内科住院医师和内分泌学奖学金。Rivas博士获得了内分泌学、糖尿病和新陈代谢委员会认证。
Maria Rivas is a highly accomplished physician executive and public company board director with more than 25 years of global experience advancing medical devices and pharmaceutical products, offering a clinically grounded, data driven perspective on innovation, regulatory strategy, and long term growth. From 2022 to 2025, Dr. Rivas served as Global Chief Medical Officer and Head of Evidence Generation for Pfizer, Inc. (NYSE: PFE), where she managed global operations of several thoand data scientists, healthcare experts, and field staff, oversaw the launch of multiple medical products, and led a digital transformation to optimize product launches and market growth and improve research capabilities. Prior to her role at Pfizer, she served as Chief Medical Officer and SVP for the healthcare biness of Merck KGaA (which operates as EMD Serono in the and Canada) from 2019 to 2022, where she led the Global Pharmacovigilance, Medical Affairs and Evidence and Value Development (HEOR) teams in over 90 countries. Prior to that, Dr. Rivas served as SVP of Global Medical Affairs at Merck & Co (also dba MSD), as VP of Global Medical Affairs at AbbVie (NYSE: ABBV), as VP of Oncology, General Medicine and Diagnostic Imaging Medical Affairs at Bayer Healthcare, and in vario roles at Eli Lilly including Head of Women's Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas was in private practice as an endocrinologist in Puerto Rico. Dr. Rivas served as a director for Medidata (NASDAQ: MDSO), a public, mid cap health technology company, until its merger with Dassault Systèmes, and served as a member of the audit and compensation committees. Dr. Rivas holds a B.A. in Biochemistry from Brandeis University and an M.D. from Columbia University's Vagelos College of Physicians and Surgeons. She completed a residency in internal medicine and a fellowship in endocrinology at New York Presbyterian Hospital and is board certified in endocrinology, diabetes, and metabolism. - Maria Rivas目前担任the healthcare business of Merck KGaA, Darmstadt的首席医疗官和高级副总裁。the healthcare business of Merck KGaA, Darmstadt在美国和加拿大担任EMD Serono，领导全球90多个国家的药物警戒、医疗事务和证据与价值开发（HEOR）团队。Rivas博士在推动高度监管行业的增长和商业化战略、全球运营、数字转型以及危机和风险管理方面有经验。在此之前，Rivas博士曾担任默克公司（MSD）全球医疗事务高级副总裁、Abbvie全球医疗事务副总裁、拜耳医疗集团肿瘤学、普通医学和诊断成像医学事务副总裁，在礼来担任各种职务，包括美国妇女健康医疗事务负责人。在加入礼来公司之前，Rivas博士在波多黎各私人执业，担任内分泌学家。Rivas博士在马萨诸塞州沃尔瑟姆的布兰代斯大学获得了生物化学学士学位，并在纽约哥伦比亚大学瓦杰洛斯内科医生和外科医生学院获得了医学博士学位。她在纽约州纽约长老会医院完成了内科住院医师和内分泌学奖学金。Rivas博士获得了内分泌学、糖尿病和新陈代谢委员会认证。
- Maria Rivas is a highly accomplished physician executive and public company board director with more than 25 years of global experience advancing medical devices and pharmaceutical products, offering a clinically grounded, data driven perspective on innovation, regulatory strategy, and long term growth. From 2022 to 2025, Dr. Rivas served as Global Chief Medical Officer and Head of Evidence Generation for Pfizer, Inc. (NYSE: PFE), where she managed global operations of several thoand data scientists, healthcare experts, and field staff, oversaw the launch of multiple medical products, and led a digital transformation to optimize product launches and market growth and improve research capabilities. Prior to her role at Pfizer, she served as Chief Medical Officer and SVP for the healthcare biness of Merck KGaA (which operates as EMD Serono in the and Canada) from 2019 to 2022, where she led the Global Pharmacovigilance, Medical Affairs and Evidence and Value Development (HEOR) teams in over 90 countries. Prior to that, Dr. Rivas served as SVP of Global Medical Affairs at Merck & Co (also dba MSD), as VP of Global Medical Affairs at AbbVie (NYSE: ABBV), as VP of Oncology, General Medicine and Diagnostic Imaging Medical Affairs at Bayer Healthcare, and in vario roles at Eli Lilly including Head of Women's Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas was in private practice as an endocrinologist in Puerto Rico. Dr. Rivas served as a director for Medidata (NASDAQ: MDSO), a public, mid cap health technology company, until its merger with Dassault Systèmes, and served as a member of the audit and compensation committees. Dr. Rivas holds a B.A. in Biochemistry from Brandeis University and an M.D. from Columbia University's Vagelos College of Physicians and Surgeons. She completed a residency in internal medicine and a fellowship in endocrinology at New York Presbyterian Hospital and is board certified in endocrinology, diabetes, and metabolism.
- Barbara Carbone
-
Barbara Carbone，在毕马威退休合伙人委员会任职。从1981年到2019年9月，她曾在跨国会计和咨询公司毕马威会计师事务所（KPMG LLP）担任多个会计和审计相关职务。退休前，她在毕马威合伙企业审计委员会任职六年，其中三年担任主席。Carbone女士担任TrueCar, Inc.的董事会成员和审计委员会主席。她担任DZS Inc.的董事会成员、审计委员会成员和薪酬委员会主席。Carbone女士还是Side by Side的董事会成员，Side by Side是一家服务于风险青年及其家人的社区非营利组织，也是位于旧金山的科学、技术和艺术博物馆Exploratorium的董事会成员。从1998年9月到2019年12月，她担任女性商业企业全国委员会的董事会成员和审计委员会主席，该委员会是美国最大的女性拥有的企业认证机构，也是女性企业主和企业家的主要倡导者。Carbone女士拥有加州州立大学萨克拉门托分校的工商管理（会计）学士学位。
Barbara Carbone has served as a director of the Company since 2022. Ms. Carbone served in several accounting and auditing related roles at KPMG LLP, a multinational accounting and advisory firm from 1981 through September 2019. Prior to her retirement she served on the KPMG Partnership Audit Committee for six years including three years as the chairperson. Ms. Carbone currently serves on the board of directors and on the audit committee of The Cooper Companies, Inc. and on the board of directors and as audit committee chair of Bob's Discount Furniture, Inc. Ms. Carbone served as the chairperson of the board of directors and a member of the workforce and compensation committees for TrueCar, Inc. from June 2023 to January 2026, and on the Audit Committee throughout her term on the board, as chair from December 2021. She served as a member of the board of directors, a member of the audit and transaction committees, and as chair of the compensation committee of DZS Inc. (NSDQ: DZSI) from January 2021 through March 2025 and as chair of the nominating and governance committee from May 2024 through March 2025. From September 1998 through December 2019, she served as a member of the board of directors, and chair of the audit committee, of the Women's Biness Enterprise National Cuncil, the largest certifier of women owned binesses in the United States and a leading advocate for women biness owners and entrepreneurs. Ms. Carbone has a Bachelor of Science in Biness Administration (Accountancy) from California State University at Sacramento. - Barbara Carbone，在毕马威退休合伙人委员会任职。从1981年到2019年9月，她曾在跨国会计和咨询公司毕马威会计师事务所（KPMG LLP）担任多个会计和审计相关职务。退休前，她在毕马威合伙企业审计委员会任职六年，其中三年担任主席。Carbone女士担任TrueCar, Inc.的董事会成员和审计委员会主席。她担任DZS Inc.的董事会成员、审计委员会成员和薪酬委员会主席。Carbone女士还是Side by Side的董事会成员，Side by Side是一家服务于风险青年及其家人的社区非营利组织，也是位于旧金山的科学、技术和艺术博物馆Exploratorium的董事会成员。从1998年9月到2019年12月，她担任女性商业企业全国委员会的董事会成员和审计委员会主席，该委员会是美国最大的女性拥有的企业认证机构，也是女性企业主和企业家的主要倡导者。Carbone女士拥有加州州立大学萨克拉门托分校的工商管理（会计）学士学位。
- Barbara Carbone has served as a director of the Company since 2022. Ms. Carbone served in several accounting and auditing related roles at KPMG LLP, a multinational accounting and advisory firm from 1981 through September 2019. Prior to her retirement she served on the KPMG Partnership Audit Committee for six years including three years as the chairperson. Ms. Carbone currently serves on the board of directors and on the audit committee of The Cooper Companies, Inc. and on the board of directors and as audit committee chair of Bob's Discount Furniture, Inc. Ms. Carbone served as the chairperson of the board of directors and a member of the workforce and compensation committees for TrueCar, Inc. from June 2023 to January 2026, and on the Audit Committee throughout her term on the board, as chair from December 2021. She served as a member of the board of directors, a member of the audit and transaction committees, and as chair of the compensation committee of DZS Inc. (NSDQ: DZSI) from January 2021 through March 2025 and as chair of the nominating and governance committee from May 2024 through March 2025. From September 1998 through December 2019, she served as a member of the board of directors, and chair of the audit committee, of the Women's Biness Enterprise National Cuncil, the largest certifier of women owned binesses in the United States and a leading advocate for women biness owners and entrepreneurs. Ms. Carbone has a Bachelor of Science in Biness Administration (Accountancy) from California State University at Sacramento.
- Cynthia L. Lucchese
-
Cynthia L. Lucchese， 2008年2月8日被选为高级副总裁和首席财务官。从2005年到2007年担任 Thoratec公司高级副总裁和首席财务官。在那之前，她在Guidant 公司（现在是波士顿技术公司的一部分）工作10年，担任多个高级金融职位，包括副总裁和风险官；企业总监和首席会计官；金融副总裁和Guidant销售公司行政总监。她之前曾在礼来公司和安永会计师事务所工作。
Cynthia L. Lucchese has over 30 years of senior corporate leadership, including nearly 20 years as a CFO, with deep expertise in strategy, M&A, international biness, finance, and accounting, complemented by extensive board and governance experience across numero healthcare and medical device companies. Ms. Lucchese served as Chief Strategy Officer for Penske Entertainment Corp from 2020 until her retirement in 2023. From 2014 to 2020, she was Chief Administrative Officer and Chief Financial Officer where she worked on the sale of Hulman and Company to Roger Penske. Previoly, she served as SVP and Chief Financial Officer of Hillenbrand (NYSE: HI) from 2008 to 2014. Prior, Ms. Lucchese was SVP and Chief Financial Officer of Thoratec from 2005 to 2007. She also held vario senior financial roles at Guidant Corporation (NYSE: GDT) from 1994 to 2005. Ms. Lucchese is a member of the board of BVI Medical, a private global ophthalmic device company, and serves as chair of the audit committee. She is a member of the board of Microtransponder, a private medical device company foced on chronic stroke recovery and serves as chair of the audit committee. Ms. Lucchese previoly served on the board of Inari Medical, a company foced on the treatment of veno thromboembolism and other veno diseases, from 2019 until its acquisition by Stryker in 2025, where she chaired the nominating & corporate governance committee and the audit committee. She also served on the board of Relievant Medsystems, Inc., a private medical device company, from 2022 until its sale to Boston Scientific in 2023, where she was chair of the audit committee. Ms. Lucchese also served on the board of Hanger, Inc., a provider of orthotic and prosthetic care services and products, until its acquisition in 2022 by Patient Square Capital, where she served on the audit and compensation committees, and on the board of Intersect ENT from 2014 until its acquisition by Medtronic, Inc. in 2022, where she served as chair of the audit committee and a member of the nominating & corporate governance committee. Ms. Lucchese served on the Board of Trtees for Indiana University from 2021 to 2025, as vice chair of the board and chair of the finance and audit committee. Ms. Lucchese holds a B.S. in Accounting and MBA from the Indiana University Kelley School of Biness. - Cynthia L. Lucchese， 2008年2月8日被选为高级副总裁和首席财务官。从2005年到2007年担任 Thoratec公司高级副总裁和首席财务官。在那之前，她在Guidant 公司（现在是波士顿技术公司的一部分）工作10年，担任多个高级金融职位，包括副总裁和风险官；企业总监和首席会计官；金融副总裁和Guidant销售公司行政总监。她之前曾在礼来公司和安永会计师事务所工作。
- Cynthia L. Lucchese has over 30 years of senior corporate leadership, including nearly 20 years as a CFO, with deep expertise in strategy, M&A, international biness, finance, and accounting, complemented by extensive board and governance experience across numero healthcare and medical device companies. Ms. Lucchese served as Chief Strategy Officer for Penske Entertainment Corp from 2020 until her retirement in 2023. From 2014 to 2020, she was Chief Administrative Officer and Chief Financial Officer where she worked on the sale of Hulman and Company to Roger Penske. Previoly, she served as SVP and Chief Financial Officer of Hillenbrand (NYSE: HI) from 2008 to 2014. Prior, Ms. Lucchese was SVP and Chief Financial Officer of Thoratec from 2005 to 2007. She also held vario senior financial roles at Guidant Corporation (NYSE: GDT) from 1994 to 2005. Ms. Lucchese is a member of the board of BVI Medical, a private global ophthalmic device company, and serves as chair of the audit committee. She is a member of the board of Microtransponder, a private medical device company foced on chronic stroke recovery and serves as chair of the audit committee. Ms. Lucchese previoly served on the board of Inari Medical, a company foced on the treatment of veno thromboembolism and other veno diseases, from 2019 until its acquisition by Stryker in 2025, where she chaired the nominating & corporate governance committee and the audit committee. She also served on the board of Relievant Medsystems, Inc., a private medical device company, from 2022 until its sale to Boston Scientific in 2023, where she was chair of the audit committee. Ms. Lucchese also served on the board of Hanger, Inc., a provider of orthotic and prosthetic care services and products, until its acquisition in 2022 by Patient Square Capital, where she served on the audit and compensation committees, and on the board of Intersect ENT from 2014 until its acquisition by Medtronic, Inc. in 2022, where she served as chair of the audit committee and a member of the nominating & corporate governance committee. Ms. Lucchese served on the Board of Trtees for Indiana University from 2021 to 2025, as vice chair of the board and chair of the finance and audit committee. Ms. Lucchese holds a B.S. in Accounting and MBA from the Indiana University Kelley School of Biness.
- Robert S. Weiss
-
Robert S. Weiss，曾担任The Cooper Companies， Inc.2008年3月担任总裁，并担任The Cooper Companies， Inc.2007年11月至2018年5月退休，担任首席执行官。2007年3月至2008年2月，他还担任Cooper公司隐形眼镜子公司CooperVision的总裁。他曾担任The Cooper Companies， Inc.的董事。2005年1月至2007年10月担任首席运营官，1995年10月至2007年0月担任执行副总裁。他曾担任The Cooper Companies， Inc.。从1989年9月到2005年1月担任首席财务官。他曾担任The Cooper Companies， Inc.。1989年至2002年3月担任财务主管。自1977年加入The Cooper Companies， Inc.以来，他曾担任The Cooper Companies， Inc.和Cooper Laboratories， Inc.（前母公司）的多个财务职位。他持有Scranton大学的会计学士学位。
Robert S. Weiss is an accomplished publiccompany leader with more than five decades of strategic, financial, and operational experience in medical devices and healthcare, offering deep expertise in the global contact lens and women's health markets and a track record of delivering long term shareholder value throughout his tenure with CooperCompanies. Mr. iss served as President from 2008 and Chief Executive Officer of CooperCompanies from 2007 until his retirement in 2018, following his role as President of CooperVision from 2007 to 2008. He previoly served as Chief Operating Officer from 2005 to 2007 and as EVP from 1995 to 2007. Earlier, he served as Chief Financial Officer from 1989 to 2005 and Treasurer from 1989 to 2002. While CEO, Mr. iss led CooperVision into the daily disposable and silicone hydrogel lens biness and helped grow its market share from 15% to more than 22%. He also played a pivotal role in the growth of CooperSurgical, contributing to its emergence as a leader in IVF and women's health. During his time as CEO, CooperCompanies achieved a 17% total shareholder return. Mr. iss served as a director of Accuray Incorporated (NASDAQ: ARAY), a company that develops, manufactures, and sells precise, innovative tumor treatment solutions. He served on its nominating and governance committee and on its audit committee until 2019. He also served as a member of the Board of Trtees of the University of Scranton in Pennsylvania until 2021, including service on its finance, advancement, and audit committees. Mr. iss holds a B.S. in Accounting from the University of Scranton. - Robert S. Weiss，曾担任The Cooper Companies， Inc.2008年3月担任总裁，并担任The Cooper Companies， Inc.2007年11月至2018年5月退休，担任首席执行官。2007年3月至2008年2月，他还担任Cooper公司隐形眼镜子公司CooperVision的总裁。他曾担任The Cooper Companies， Inc.的董事。2005年1月至2007年10月担任首席运营官，1995年10月至2007年0月担任执行副总裁。他曾担任The Cooper Companies， Inc.。从1989年9月到2005年1月担任首席财务官。他曾担任The Cooper Companies， Inc.。1989年至2002年3月担任财务主管。自1977年加入The Cooper Companies， Inc.以来，他曾担任The Cooper Companies， Inc.和Cooper Laboratories， Inc.（前母公司）的多个财务职位。他持有Scranton大学的会计学士学位。
- Robert S. Weiss is an accomplished publiccompany leader with more than five decades of strategic, financial, and operational experience in medical devices and healthcare, offering deep expertise in the global contact lens and women's health markets and a track record of delivering long term shareholder value throughout his tenure with CooperCompanies. Mr. iss served as President from 2008 and Chief Executive Officer of CooperCompanies from 2007 until his retirement in 2018, following his role as President of CooperVision from 2007 to 2008. He previoly served as Chief Operating Officer from 2005 to 2007 and as EVP from 1995 to 2007. Earlier, he served as Chief Financial Officer from 1989 to 2005 and Treasurer from 1989 to 2002. While CEO, Mr. iss led CooperVision into the daily disposable and silicone hydrogel lens biness and helped grow its market share from 15% to more than 22%. He also played a pivotal role in the growth of CooperSurgical, contributing to its emergence as a leader in IVF and women's health. During his time as CEO, CooperCompanies achieved a 17% total shareholder return. Mr. iss served as a director of Accuray Incorporated (NASDAQ: ARAY), a company that develops, manufactures, and sells precise, innovative tumor treatment solutions. He served on its nominating and governance committee and on its audit committee until 2019. He also served as a member of the Board of Trtees of the University of Scranton in Pennsylvania until 2021, including service on its finance, advancement, and audit committees. Mr. iss holds a B.S. in Accounting from the University of Scranton.
- Lawrence E. Kurzius
-
Lawrence E. Kurzius是Global Consumer Business公司的总裁兼首席行政官（2013年至今），也是 McCormick International 公司的总裁（2008年至2013年）。
Lawrence E. Kurzius is a highly respected global biness leader who has extensive public company leadership, including as CEO, and experience in long range strategic planning, consumer marketing, human capital management, and enterprise risk management, and has demonstrated a strong record of driving performance and stained growth throughout his career leading multinational organizations. Mr. Kurzi served as the Chief Executive Officer of McCormick & Company, Incorporated (NYSE: MKC) from 2016 to 2023 and as its President from 2015 to 2022. While he was CEO, the company more than doubled its market value. He previoly held roles of increasing responsibility at McCormick, including President and Chief Operating Officer from 2015 to 2016, President of McCormick's global consumer biness from 2013 to 2016, Chief Administrative Officer from 2013 to 2015, President of the international biness from 2008 to 2013, and President of EMEA from 2007 to 2008. Previoly, Mr. Kurzi was the Chief Executive Officer of Zatarain's, where he worked for 12 years before the company was acquired by McCormick. Prior to this, Mr. Kurzi was a marketing executive with the Quaker Oats Company and Mars Inc.'s Ben's Original (formerly Uncle Ben's). Mr. Kurzi currently serves as the Chairman of the Board of Elanco Animal Health Inc. (NYSE: ELAN) since 2024; he has served as a member of its board as ll as on its corporate governance committee, audit committee and as chair of its compensation and human capital committee since 2018. He also serves on the board of Lamb ston (NYSE: LW), as ll as on its compensation and human capital committee and nominating and corporate governance committee, since July 2025. Mr. Kurzi previoly served as a member of the board of McCormick until 2025, as the Executive Chairman from 2023 to 2024 and as the Chairman from 2017 to 2023. Mr. Kurzi holds an A.B. in economics from Princeton University, graduating magna cum laude. - Lawrence E. Kurzius是Global Consumer Business公司的总裁兼首席行政官（2013年至今），也是 McCormick International 公司的总裁（2008年至2013年）。
- Lawrence E. Kurzius is a highly respected global biness leader who has extensive public company leadership, including as CEO, and experience in long range strategic planning, consumer marketing, human capital management, and enterprise risk management, and has demonstrated a strong record of driving performance and stained growth throughout his career leading multinational organizations. Mr. Kurzi served as the Chief Executive Officer of McCormick & Company, Incorporated (NYSE: MKC) from 2016 to 2023 and as its President from 2015 to 2022. While he was CEO, the company more than doubled its market value. He previoly held roles of increasing responsibility at McCormick, including President and Chief Operating Officer from 2015 to 2016, President of McCormick's global consumer biness from 2013 to 2016, Chief Administrative Officer from 2013 to 2015, President of the international biness from 2008 to 2013, and President of EMEA from 2007 to 2008. Previoly, Mr. Kurzi was the Chief Executive Officer of Zatarain's, where he worked for 12 years before the company was acquired by McCormick. Prior to this, Mr. Kurzi was a marketing executive with the Quaker Oats Company and Mars Inc.'s Ben's Original (formerly Uncle Ben's). Mr. Kurzi currently serves as the Chairman of the Board of Elanco Animal Health Inc. (NYSE: ELAN) since 2024; he has served as a member of its board as ll as on its corporate governance committee, audit committee and as chair of its compensation and human capital committee since 2018. He also serves on the board of Lamb ston (NYSE: LW), as ll as on its compensation and human capital committee and nominating and corporate governance committee, since July 2025. Mr. Kurzi previoly served as a member of the board of McCormick until 2025, as the Executive Chairman from 2023 to 2024 and as the Chairman from 2017 to 2023. Mr. Kurzi holds an A.B. in economics from Princeton University, graduating magna cum laude.
- Walter M Rosebrough, Jr.
-
Walter M Rosebrough, Jr.自2007年10月担任STERIS Corporation公司的董事、总裁兼首席执行官。2005年2月至2007年9月，他担任 Coastal Hydraulics公司的总裁兼首席执行官，这是一家2005年由他购买的液压和气压系统公司，并且他也继续担任非执行董事长。之前，Rosebrough 先生在医疗行业工作了将近20年并同时担任Hill-Rom Holdings和Hillenbrand Industries的高管， Hillenbrand Industries公司在全世界提供医疗设备和相关服务。他担任 Hillenbrand Industries公司的总裁兼全球支持系统首席执行官， Hill-Rom Holdings公司的总裁兼首席执行官。
Walter M Rosebrough, Jr. currently serves as CEO Emerit and Senior Advisor of STERIS plc (NYSE: STE), a global medical device biness foced on infection prevention products and services. During his tenure as CEO of STERIS from 2007 to 2021, STERIS's shareholders received an 18% annualized return compared with 10% for the S&P 500, and the company's market capitalization increased from $2 billion to $20 billion. His career also includes nearly two decades at Hill Rom purchased by Baxter (NYSE: BAX), a global leader in patient support systems, therapeutic products, and workflow information technology where he held senior executive positions, including President and CEO of Support Systems International and President and CEO of Hill Rom. Mr. Rosebrough has served on several healthcare indtry boards, including the Association for the Advancement of Medical Instrumentation (AAMI), where he currently serves as chair; the Advanced Medical Technology Association (AdvaMed), where he was a member of the executive committee and chair of the compensation and finance committees; and the Medical Device Manufacturers Association. Mr. Rosebrough currently serves as independent chair of the board of Varex Imaging (NASDAQ: VREX), and independent member of the board of Precipart, a private company. Mr. Rosebrough holds an MBA from Stanford University, and a BIE from Kettering University. Pursuant to a letter agreement, dated December 22, 2025, beten the Company and Browning st, LP, Mr. Rosebrough was appointed to the Board and the Company included Mr. Rosebrough as a nominee for election at the Annual Meeting. - Walter M Rosebrough, Jr.自2007年10月担任STERIS Corporation公司的董事、总裁兼首席执行官。2005年2月至2007年9月，他担任 Coastal Hydraulics公司的总裁兼首席执行官，这是一家2005年由他购买的液压和气压系统公司，并且他也继续担任非执行董事长。之前，Rosebrough 先生在医疗行业工作了将近20年并同时担任Hill-Rom Holdings和Hillenbrand Industries的高管， Hillenbrand Industries公司在全世界提供医疗设备和相关服务。他担任 Hillenbrand Industries公司的总裁兼全球支持系统首席执行官， Hill-Rom Holdings公司的总裁兼首席执行官。
- Walter M Rosebrough, Jr. currently serves as CEO Emerit and Senior Advisor of STERIS plc (NYSE: STE), a global medical device biness foced on infection prevention products and services. During his tenure as CEO of STERIS from 2007 to 2021, STERIS's shareholders received an 18% annualized return compared with 10% for the S&P 500, and the company's market capitalization increased from $2 billion to $20 billion. His career also includes nearly two decades at Hill Rom purchased by Baxter (NYSE: BAX), a global leader in patient support systems, therapeutic products, and workflow information technology where he held senior executive positions, including President and CEO of Support Systems International and President and CEO of Hill Rom. Mr. Rosebrough has served on several healthcare indtry boards, including the Association for the Advancement of Medical Instrumentation (AAMI), where he currently serves as chair; the Advanced Medical Technology Association (AdvaMed), where he was a member of the executive committee and chair of the compensation and finance committees; and the Medical Device Manufacturers Association. Mr. Rosebrough currently serves as independent chair of the board of Varex Imaging (NASDAQ: VREX), and independent member of the board of Precipart, a private company. Mr. Rosebrough holds an MBA from Stanford University, and a BIE from Kettering University. Pursuant to a letter agreement, dated December 22, 2025, beten the Company and Browning st, LP, Mr. Rosebrough was appointed to the Board and the Company included Mr. Rosebrough as a nominee for election at the Annual Meeting.
高管简历
中英对照 | 中文 | 英文- Albert G. White III
Albert G. White III，他曾担任The Cooper Companies， Inc.的总裁兼首席执行官和成员。自2018年5月起担任董事会成员。此前，他从2016年11月起担任首席财务官，直到被任命为首席执行官，他还分别从2015年12月和2011年7月担任执行副总裁和首席战略官。从2015年8月到2018年5月，White先生还负责The Cooper Companies， Inc.的女性医疗保健业务，并担任Cooper Medical Inc. （CooperSurgical的母公司）的首席执行官。此前，他从2007年11月到2013年3月担任投资者关系副总裁，从2006年4月到2012年12月担任副总裁兼财务主管。在加入本公司之前，White先生曾担任KeyBank Capital Markets董事三年，并在KeyBank National Association担任多个领导职位。他持有Virginia Tech的金融学士学位和工商管理硕士学位。
Albert G. White III has served as President & Chief Executive Officer and as a member of Board of Directors since May 2018. Under his leadership, CooperCompanies has developed into a unified, synergistic operating company and global medical device leader – driving strong revenue and profit growth through organizational evolution while elevating CooperVision to the world's #1 contact lens company by arers and CooperSurgical to the global leader in fertility devices and a U.S. leader in highrisk labor and delivery safety. Prior to his appointment as CEO, Mr. White served in vario leadership roles across CooperCompanies, developing an intimate understanding of the biness and its markets. He served as Chief Financial Officer from November 2016 to May 2018 and as EVP and Chief Strategy Officer beginning in 2015 and 2011, respectively. From Augt 2015 to May 2018, he also led the Company's women's healthcare biness and served as CEO of Cooper Medical Inc., the parent company of CooperSurgical. Earlier in his tenure at CooperCompanies, he held the roles of VP, Investor Relations (2007–2013) and VP and Treasurer (2006–2012). Before joining CooperCompanies, Mr. White spent three years as a Director at KeyBanc Capital Markets and held numero positions of increasing responsibility within KeyBank National Association over the prior eight years. Mr. White also serves as a member of the Board of Directors of Evol, Inc. (NASDAQ: EOLS), a performance beauty company building an aesthetic portfolio of consumer brands. He is Chair of the Compensation Committee and a member of the Audit Committee. Mr. White holds a B.S. in Finance and an MBA, both from Virginia Tech.- Albert G. White III，他曾担任The Cooper Companies， Inc.的总裁兼首席执行官和成员。自2018年5月起担任董事会成员。此前，他从2016年11月起担任首席财务官，直到被任命为首席执行官，他还分别从2015年12月和2011年7月担任执行副总裁和首席战略官。从2015年8月到2018年5月，White先生还负责The Cooper Companies， Inc.的女性医疗保健业务，并担任Cooper Medical Inc. （CooperSurgical的母公司）的首席执行官。此前，他从2007年11月到2013年3月担任投资者关系副总裁，从2006年4月到2012年12月担任副总裁兼财务主管。在加入本公司之前，White先生曾担任KeyBank Capital Markets董事三年，并在KeyBank National Association担任多个领导职位。他持有Virginia Tech的金融学士学位和工商管理硕士学位。
- Albert G. White III has served as President & Chief Executive Officer and as a member of Board of Directors since May 2018. Under his leadership, CooperCompanies has developed into a unified, synergistic operating company and global medical device leader – driving strong revenue and profit growth through organizational evolution while elevating CooperVision to the world's #1 contact lens company by arers and CooperSurgical to the global leader in fertility devices and a U.S. leader in highrisk labor and delivery safety. Prior to his appointment as CEO, Mr. White served in vario leadership roles across CooperCompanies, developing an intimate understanding of the biness and its markets. He served as Chief Financial Officer from November 2016 to May 2018 and as EVP and Chief Strategy Officer beginning in 2015 and 2011, respectively. From Augt 2015 to May 2018, he also led the Company's women's healthcare biness and served as CEO of Cooper Medical Inc., the parent company of CooperSurgical. Earlier in his tenure at CooperCompanies, he held the roles of VP, Investor Relations (2007–2013) and VP and Treasurer (2006–2012). Before joining CooperCompanies, Mr. White spent three years as a Director at KeyBanc Capital Markets and held numero positions of increasing responsibility within KeyBank National Association over the prior eight years. Mr. White also serves as a member of the Board of Directors of Evol, Inc. (NASDAQ: EOLS), a performance beauty company building an aesthetic portfolio of consumer brands. He is Chair of the Compensation Committee and a member of the Audit Committee. Mr. White holds a B.S. in Finance and an MBA, both from Virginia Tech.
- Brian G. Andrews
Brian G. Andrews于2020年12月起担任执行副总裁兼首席财务官兼财务主管。他此前于2018年5月起担任The Cooper Companies, Inc.高级副总裁、首席财务官兼财务主管，2013年1月起担任财务主管，2014年11月起担任副总裁。2017年6月至2018年5月，他还担任CooperSurgical全球物流和服务副总裁。Andrews先生曾于2006年4月至2012年12月担任公司助理财务主任。在加入Cooper之前，他曾于2002年至2006年在KeyBanc Capital Markets和2000年至2001年在ING Barings担任多个公司和投资银行职位。他拥有哥伦比亚大学经济学学士学位。
Brian G. Andrews has served as Executive Vice President since December 2020, Senior Vice President, Chief Financial Officer and Treasurer since May 2018, Treasurer since January 2013 and Vice President since November 2014. He also served as Vice President, Global Logistics and Service for CooperSurgical, a position he held from June 2017 to May 2018. Mr. Andrews previoly served as Assistant Treasurer for the Company from April 2006 to December 2012. Prior to joining the Company, he held vario corporate and investment banking positions at KeyBanc Capital Markets from 2002 to 2006 and at ING Barings from 2000 to 2001.- Brian G. Andrews于2020年12月起担任执行副总裁兼首席财务官兼财务主管。他此前于2018年5月起担任The Cooper Companies, Inc.高级副总裁、首席财务官兼财务主管，2013年1月起担任财务主管，2014年11月起担任副总裁。2017年6月至2018年5月，他还担任CooperSurgical全球物流和服务副总裁。Andrews先生曾于2006年4月至2012年12月担任公司助理财务主任。在加入Cooper之前，他曾于2002年至2006年在KeyBanc Capital Markets和2000年至2001年在ING Barings担任多个公司和投资银行职位。他拥有哥伦比亚大学经济学学士学位。
- Brian G. Andrews has served as Executive Vice President since December 2020, Senior Vice President, Chief Financial Officer and Treasurer since May 2018, Treasurer since January 2013 and Vice President since November 2014. He also served as Vice President, Global Logistics and Service for CooperSurgical, a position he held from June 2017 to May 2018. Mr. Andrews previoly served as Assistant Treasurer for the Company from April 2006 to December 2012. Prior to joining the Company, he held vario corporate and investment banking positions at KeyBanc Capital Markets from 2002 to 2006 and at ING Barings from 2000 to 2001.
- Holly R. Sheffield
Holly R. Sheffield，自2020年7月起担任CooperSurgical， Inc., The Cooper Companies, Inc.女性医疗保健业务的总裁。此前，她于2018年6月至2020年7月担任执行副总裁兼首席战略官。在加入公司之前，她拥有超过20年的投资银行经验。2009年至2018年5月，她从UBS Securities LLC加入Cooper，担任董事总经理，医疗技术全球主管。2000年至2009年，她在Credit Suisse任职；1997年至2000年，她在Donaldson， Lufkin & Jenrette任职，直到该公司被Credit Suisse收购。她获得Cornell大学的理学士学位和Columbia Business School的工商管理硕士学位。
Holly R. Sheffield has served as President of CooperSurgical since July 2020. Previoly, she served as Executive Vice President & Chief Strategy Officer from June 2018 to July 2020. Prior to joining the Company, Ms. Sheffield had over 20 years of experience in investment banking. She joined CooperSurgical from UBS Securities LLC, where she was a Managing Director, Global Head of Medical Technology from 2009 to May 2018. From 2000 to 2009, Ms. Sheffield was at Credit Suisse and from 1997 2000, Ms. Sheffield was at Donaldson, Lufkin & Jenrette until it was acquired by Credit Suisse.- Holly R. Sheffield，自2020年7月起担任CooperSurgical， Inc., The Cooper Companies, Inc.女性医疗保健业务的总裁。此前，她于2018年6月至2020年7月担任执行副总裁兼首席战略官。在加入公司之前，她拥有超过20年的投资银行经验。2009年至2018年5月，她从UBS Securities LLC加入Cooper，担任董事总经理，医疗技术全球主管。2000年至2009年，她在Credit Suisse任职；1997年至2000年，她在Donaldson， Lufkin & Jenrette任职，直到该公司被Credit Suisse收购。她获得Cornell大学的理学士学位和Columbia Business School的工商管理硕士学位。
- Holly R. Sheffield has served as President of CooperSurgical since July 2020. Previoly, she served as Executive Vice President & Chief Strategy Officer from June 2018 to July 2020. Prior to joining the Company, Ms. Sheffield had over 20 years of experience in investment banking. She joined CooperSurgical from UBS Securities LLC, where she was a Managing Director, Global Head of Medical Technology from 2009 to May 2018. From 2000 to 2009, Ms. Sheffield was at Credit Suisse and from 1997 2000, Ms. Sheffield was at Donaldson, Lufkin & Jenrette until it was acquired by Credit Suisse.
- Gerard H. Warner III
Gerard H. Warner III 自2022年2月起担任CooperVision，Inc.总裁。他曾于2019年4月至2022年1月担任CooperVision美洲和全球商业职能执行副总裁，并于2015年5月至2019年3月担任美洲总裁。2012年5月至2015年4月，Warner曾在CooperVision担任过多个其他副总裁和高级副总裁职位。在加入CooperVision之前，H. Warner曾在博士伦担任过17年的营销和管理职务。Warner先生获得了理科学士学位——来自维拉诺瓦大学的商业管理和罗切斯特大学西蒙商学院的工商管理硕士学位。
Gerard H. Warner III has served as President, CooperVision from February 2022. He previoly served as Executive Vice President, Americas & Global Commercial Functions of CooperVision from April 2019 to January 2022 and as President, Americas from May 2015 to March 2019. Mr. Warner served in vario other Vice President and Senior Vice President positions with CooperVision from May 2012 through April 2015. Prior to joining CooperVision, Mr. Warner spent 17 years at Bach + Lomb in a variety of marketing and management roles.- Gerard H. Warner III 自2022年2月起担任CooperVision，Inc.总裁。他曾于2019年4月至2022年1月担任CooperVision美洲和全球商业职能执行副总裁，并于2015年5月至2019年3月担任美洲总裁。2012年5月至2015年4月，Warner曾在CooperVision担任过多个其他副总裁和高级副总裁职位。在加入CooperVision之前，H. Warner曾在博士伦担任过17年的营销和管理职务。Warner先生获得了理科学士学位——来自维拉诺瓦大学的商业管理和罗切斯特大学西蒙商学院的工商管理硕士学位。
- Gerard H. Warner III has served as President, CooperVision from February 2022. He previoly served as Executive Vice President, Americas & Global Commercial Functions of CooperVision from April 2019 to January 2022 and as President, Americas from May 2015 to March 2019. Mr. Warner served in vario other Vice President and Senior Vice President positions with CooperVision from May 2012 through April 2015. Prior to joining CooperVision, Mr. Warner spent 17 years at Bach + Lomb in a variety of marketing and management roles.
- Daniel G. McBride
Daniel G. McBride， 2013年11月起担任执行副总裁兼首席运营官。2014年2月至2022年2月，他曾担任the Cooper Companies， Inc.隐形眼镜子公司CooperVision， Inc.的总裁。从2011年7月到2013年10月担任The Cooper Companies， Inc.的首席风险官。2007年11月至2014年1月担任总法律顾问，2006年7月至2013年10月担任副总裁。从2005年2月到2007年11月，他还担任高级法律顾问。在加入公司之前，从1998年10月到2005年2月，他是Latham & Watkins LLP的律师，专注于并购和企业融资事务。McBride持有Santa Clara大学的金融学士学位和Stanford Law School的法学博士学位。
Daniel G. McBride has served as Executive Vice President and Chief Operating Officer since November 2013 and as General Counsel and Secretary since October 2025. He previoly served as President of CooperVision from February 2014 through February 2022, as Chief Risk Officer from July 2011 through October 2013, as General Counsel from November 2007 through January 2014, and as Vice President from July 2006 through October 2013. He also served as Senior Counsel from February 2005 through November 2007. Prior to joining the Company, Mr. McBride was an attorney with Latham & Watkins LLP from October 1998 to February 2005, concentrating on mergers and acquisitions and corporate finance matters.- Daniel G. McBride， 2013年11月起担任执行副总裁兼首席运营官。2014年2月至2022年2月，他曾担任the Cooper Companies， Inc.隐形眼镜子公司CooperVision， Inc.的总裁。从2011年7月到2013年10月担任The Cooper Companies， Inc.的首席风险官。2007年11月至2014年1月担任总法律顾问，2006年7月至2013年10月担任副总裁。从2005年2月到2007年11月，他还担任高级法律顾问。在加入公司之前，从1998年10月到2005年2月，他是Latham & Watkins LLP的律师，专注于并购和企业融资事务。McBride持有Santa Clara大学的金融学士学位和Stanford Law School的法学博士学位。
- Daniel G. McBride has served as Executive Vice President and Chief Operating Officer since November 2013 and as General Counsel and Secretary since October 2025. He previoly served as President of CooperVision from February 2014 through February 2022, as Chief Risk Officer from July 2011 through October 2013, as General Counsel from November 2007 through January 2014, and as Vice President from July 2006 through October 2013. He also served as Senior Counsel from February 2005 through November 2007. Prior to joining the Company, Mr. McBride was an attorney with Latham & Watkins LLP from October 1998 to February 2005, concentrating on mergers and acquisitions and corporate finance matters.